Pfizer Inc. reported second-quarter 2025 revenues of $14.7 billion, marking a 10% operational growth year-over-year. The company reaffirmed its 2025 revenue guidance between $61.0 and $64.0 billion while raising its adjusted diluted earnings per share (EPS) guidance by $0.10, now estimated to be between $2.90 and $3.10. Key revenue drivers included significant increases in sales from products like Vyndaqel, Comirnaty, and Paxlovid, despite challenges from higher manufacturer discounts due to the Inflation Reduction Act.
In terms of cost management, Pfizer is on track to achieve approximately $7.2 billion in net cost savings from ongoing initiatives by the end of 2027. The company has allocated capital towards research and development, investing $4.7 billion in the first half of 2025, while returning $4.9 billion to shareholders through dividends. Pfizer's effective tax rate decreased due to a favorable jurisdictional mix, contributing positively to its financial performance in the quarter.
linkAug 05, 2025 07:08:22
Pfizer Inc. reported first-quarter 2025 revenues of $13.7 billion, a decrease of 8% compared to the same period last year. The company achieved a reported diluted EPS of $0.52 and an adjusted diluted EPS of $0.92, reflecting a 12% increase in adjusted income year-over-year. Pfizer is on track to meet its cost savings targets, expecting approximately $4.5 billion in net savings by the end of 2025, with additional savings anticipated through 2027. The company reaffirmed its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion and adjusted diluted EPS in the range of $2.80 to $3.00, excluding potential impacts from future tariffs and trade policies.
In terms of product performance, Pfizer experienced a significant decline in Paxlovid revenues, down 75% year-over-year, largely due to decreased COVID-19 infections. However, growth was noted in other product categories, such as the Vyndaqel family and Comirnaty, which saw operational increases of 33% and 62%, respectively. The company also announced notable developments in its product pipeline, including the expansion of the RSV vaccine indication and positive results from various clinical trials. Additionally, Pfizer completed a significant sale of its investment in Haleon, generating approximately $3.3 billion in net cash proceeds.
linkApr 29, 2025 08:02:49
Pfizer Inc. announced its financial results for the full year 2024, reporting revenues of $63.6 billion, which reflects a 7% operational growth compared to the previous year. Notably, revenues from non-COVID products grew by 12%, and the company achieved significant cost savings of approximately $4 billion through its ongoing cost realignment program. Additionally, fourth-quarter revenues reached $17.8 billion, marking a 22% year-over-year operational growth, driven by robust sales from various products including the legacy Seagen portfolio and Vyndaqel family.
However, the company faced challenges with a significant decline in revenues from Comirnaty, which decreased by 38% due to fewer COVID-19 vaccinations. The fourth-quarter also saw a reported diluted EPS of $0.07, a notable improvement from a loss in the prior year, but still reflects the impact of a $3.5 billion revenue reversal related to Paxlovid sales. Furthermore, the company reported a $2.9 billion non-cash impairment charge in the fourth quarter, indicating difficulties in its product pipeline and potential future revenue streams.
linkFeb 04, 2025 08:11:20
Pfizer has provided its revenue guidance for 2025, estimating a range between $61.0 billion and $64.0 billion. The company also expects an adjusted diluted earnings per share (EPS) of $2.80 to $3.00, indicating operational growth of 10% to 18% from the midpoint of 2024 guidance. Pfizer achieved $4.0 billion in net cost savings through 2024 and anticipates an additional $500 million in savings for 2025, as part of its ongoing cost management efforts. The first phase of its manufacturing optimization program is also on track to deliver savings by late 2025, aimed at improving gross margin performance.
On the downside, Pfizer's revenue guidance for 2025 includes an expected unfavorable impact of approximately $1 billion related to changes from the Inflation Reduction Act, specifically affecting Medicare Part D. Additionally, the company anticipates revenue from its COVID-19 products to remain largely consistent with 2024, but this is after excluding approximately $1.2 billion of non-recurring revenue from Paxlovid in 2024. The company also faces challenges from generic competition for certain products and the potential impact of reduced demand for COVID-19 treatments as the market stabilizes.
linkDec 17, 2024 07:47:10
Pfizer announced impressive financial results for the third quarter of 2024, with revenues reaching $17.7 billion, marking a 31% increase compared to the same period last year. The company attributed this growth to strong sales across its product portfolio, particularly in oncology and COVID-19 treatments. Notably, they raised their full-year revenue guidance to a range of $61.0 to $64.0 billion and adjusted diluted earnings per share (EPS) guidance to $2.75 to $2.95, reflecting confidence in their ongoing commercial execution and cost reduction initiatives.
Despite the positive results, there were some challenges highlighted, including a significant decline in sales for certain products like Xeljanz and Ibrance, which faced competitive pressures and market changes. Additionally, the withdrawal of Oxbryta due to safety concerns indicates potential risks in their product pipeline. However, the overall outlook remains optimistic, bolstered by new product approvals and a strong operational performance in non-COVID related products.
linkOct 29, 2024 08:06:28
Pfizer has announced the election of Tim Buckley to its Board of Directors, effective immediately. Buckley, who recently retired as the CEO of Vanguard, brings extensive experience in investment management and financial operations. His appointment expands the board to 14 members, with 13 being independent, which may enhance governance and oversight for the company. Pfizer's leadership expressed confidence that Buckley's expertise will benefit both the company and its shareholders.
In his statement, Buckley expressed his admiration for Pfizer's commitment to innovation and improving patient health. He looks forward to collaborating with the board and management to support advancements that positively impact patients' lives while also focusing on shareholder value. This development reflects Pfizer's ongoing efforts to strengthen its leadership team with individuals who have a proven track record in their respective fields.
linkOct 15, 2024 07:18:26
Pfizer's second-quarter 2024 results show a 2% revenue increase to $13.3 billion, driven by strong performance in its product portfolio, especially in Oncology. The company raised its full-year revenue guidance to $59.5-$62.5 billion. However, reported diluted EPS dropped significantly to $0.01 due to one-time costs. Pfizer is also implementing a cost-saving program expected to save $4 billion by the end of 2024.
linkJul 30, 2024 08:04:27
Pfizer has modified its 2022 and 2023 Total Shareholder Return Units (TSRUs) to encourage employee retention and improve stock price recovery. The changes allow employees to extend the duration of their TSRUs by two years, giving them more time to benefit from potential stock price increases. This decision comes after a decline in stock value following high COVID-19 vaccination rates. The modifications aim to align employee interests with shareholders and enhance motivation, though participation is voluntary.
linkJul 26, 2024 11:09:20
Pfizer appoints Cyrus Taraporevala, a seasoned executive with experience in investment management, to its Board of Directors. His background in global operations and financial markets is expected to benefit Pfizer's shareholders. Taraporevala's election aims to enhance the diversity of experience and perspectives on the Board, reflecting Pfizer's commitment to innovation and quality healthcare products.
linkJul 01, 2024 08:07:18
Pfizer reports $14.9 billion revenues, with a 19% operational decline due to lower Comirnaty and Paxlovid sales. Adjusted diluted EPS is $0.82, showing a 33% decrease. The company aims for $4 billion net cost savings by 2024 end and raises adjusted EPS guidance to $2.15-$2.35. Strong growth in non-COVID products is highlighted, particularly in oncology and key brands. Pfizer maintains its 2024 revenue guidance of $58.5-$61.5 billion. Capital allocation includes $2.5 billion in R&D and $2.4 billion in dividends, with no share repurchases planned for 2024.
linkMay 01, 2024 08:11:26